MCM
ABUS icon

MAI Capital Management’s Arbutus Biopharma ABUS Stock Holding History

MAI Capital Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-655
Closed -$2.95K – 2120
2026
Q1 		$2.95K Buy
655
+54
+9% +$236 ﹤0.01% 3767
2025
Q4 		$2.89K Hold
601
– – ﹤0.01% 3317
2025
Q3 		$2.73K Hold
601
– – ﹤0.01% 3231
2025
Q2 		$1.86K Buy
+601
New +$2K ﹤0.01% 3446

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

MAI Capital Management's ABUS Position: Q2 2026 in Review

MAI Capital Management sold out of Arbutus Biopharma (ABUS) in Q2 2026, closing a stake of 655 shares — an estimated $2.95K sold.

MAI Capital Management first reported a position in ABUS in Q2 2025 and held it in 4 quarters. The position peaked at $2.95K in Q1 2026. 176 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • MAI Capital Management reported no remaining Arbutus Biopharma position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 655 Arbutus Biopharma shares in Q2 2026, an estimated $2.95K.
  • MAI Capital Management first reported a position in Arbutus Biopharma in Q2 2025 and held it in 4 quarters.
  • MAI Capital Management's Arbutus Biopharma position peaked at $2.95K in Q1 2026.
  • 176 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.